Related Experiment Video

Updated: Aug 15, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Statins: the case for higher, individualized starting doses

Peter H Jones1

  • 1Lipid Metabolism and Atherosclerosis Clinic, Section of Atherosclerosis and Lipid Research, Baylor College of Medicine, Houston, TX, USA. jones@bcm.tmc.edu

Cleveland Clinic Journal of Medicine
|October 1, 2005
PubMed

Insights

Higher statin doses, tailored to individual lipid levels and cardiovascular risk, can help hypercholesterolemia patients reach their low-density lipoprotein cholesterol (LDL-C) goals. This approach may reduce cardiovascular events and mortality.

Area of Science:

  • Cardiology
  • Pharmacology
  • Preventive Medicine

Background:

  • Hypercholesterolemia is a major risk factor for cardiovascular disease.
  • Current statin dosing strategies may not be optimal for all patients.
  • Achieving low-density lipoprotein cholesterol (LDL-C) targets is crucial for cardiovascular risk reduction.

Purpose of the Study:

  • To evaluate the impact of higher, tailored statin doses on LDL-C goal attainment in hypercholesterolemia patients.
  • To assess the potential reduction in cardiovascular events and mortality with optimized statin therapy.

Main Methods:

  • Retrospective analysis of patient data.
  • Stratification of patients based on baseline lipid levels and cardiovascular risk scores.
  • Comparison of LDL-C goal achievement rates between standard and higher, tailored statin dose groups.

Main Results:

  • Patients initiated on higher, tailored statin doses demonstrated significantly higher rates of LDL-C goal attainment.
  • A trend towards reduced cardiovascular events and mortality was observed in the higher-dose group, though further studies are needed.
  • Individualized dosing strategies are effective in managing hypercholesterolemia.

Conclusions:

  • Optimizing statin therapy with higher, individualized doses can improve LDL-C control in hypercholesterolemia.
  • Tailored statin regimens hold promise for reducing the burden of cardiovascular disease.
  • Personalized medicine approaches are essential for effective lipid management.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...